Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus

Virology Journal

Volumn 4, Issue , 2007, Pages

  Liu, Changbao ^a   Day, Nicole D ^a   Branigan, Patrick J ^a   Gutshall, Lester L ^a   Sarisky, Robert T ^a   Del Vecchio, Alfred M ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; PALIVIZUMAB; EPITOPE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; VIRUS FUSION PROTEIN;

ANTIGEN BINDING; ARTICLE; GENE FUSION; GENE MUTATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MUTATION; SERODIAGNOSIS; VIROLOGY;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYDRANGEA RINGSPOT VIRUS;

ANTIBODIES, MONOCLONAL; EPITOPES; HUMANS; MUTATION; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL FUSION PROTEINS;

EID: 34547876851     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-71     Document Type: Article

References (30)

1. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. LG Stensballe JK Devasundaram EA Simoes, Pediatr Infect Dis J 2003 22 S21 32 10.1097/00006454-200302001-00004 12671449
2. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. LJ Anderson P Bingham JC Hierholzer, J Virol 1988 62 4232 4238 2459412
3. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. JA Beeler K van Wyke Coelingh, J Virol 1989 63 2941 2950 2470922
4. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. B Garcia-Barreno C Palomo C Penas T Delgado P Perez-Brena JA Melero, J Virol 1989 63 925 932 2463385
5. Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization. M Trudel F Nadon C Seguin P Payment PJ Talbot, Can J Microbiol 1987 33 933 938 2446731
6. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. S Johnson C Oliver GA Prince VG Hemming DS Pfarr SC Wang M Dormitzer J O'Grady S Koenig JK Tamura R Woods G Bansal D Couchenour E Tsao WC Hall JF Young, J Infect Dis 1997 176 1215 1224 9359721
7. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. TF Feltes AK Cabalka HC Meissner FM Piazza DA Carlin FH Top Jr. EM Connor HM Sondheimer, J Pediatr 2003 143 532 540 10.1067/S0022-3476(03)00454- 2 14571236
8. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. JP DeVincenzo CB Hall DW Kimberlin PJ Sanchez WJ Rodriguez BA Jantausch L Corey JS Kahn JA Englund JA Suzich FJ Palmer-Hill L Branco S Johnson NK Patel FM Piazza, J Infect Dis 2004 190 975 978 10.1086/423213 15295704
9. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. H Wu DS Pfarr S Johnson YA Brewah RM Woods NK Patel WI White JF Young PA Kiener, J Mol Biol 2007 368 652 665 10.1016/j.jmb.2007.02.024 17362988
10. Anti-RSV Antibodies. JF Young S Koenig LS Johnson, USA, MedImmune, Inc. 2004
11. In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants. X Zhao E Liu FP Chen WM Sullender, J Virol 2006 80 11651 11657 17005645 10.1128/JVI.01387-06
12. In vivo selection of respiratory syncytial viruses resistant to palivizumab. X Zhao WM Sullender, J Virol 2005 79 3962 3968 15767398 10.1128/JVI.79.7.3962-3968.2005
13. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. X Zhao FP Chen AG Megaw WM Sullender, J Infect Dis 2004 190 1941 1946 10.1086/425515 15529258
14. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. X Zhao FP Chen WM Sullender, Virology 2004 318 608 612 10.1016/j.virol.2003.10.018 14972528
15. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. G Taylor EJ Stott J Furze J Ford P Sopp, J Gen Virol 1992 73 ( Pt 9) 2217 2223 1383403
16. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. DE Everitt CB Davis K Thompson R DiCicco B Ilson SG Demuth DJ Herzyk DK Jorkasky, J Infect Dis 1996 174 463 469 8769601
17. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. PR Wyde DK Moore T Hepburn CL Silverman TG Porter M Gross G Taylor SG Demuth SB Dillon, Pediatr Res 1995 38 543 550 10.1203/00006450-199510000-00012 8559607
18. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Arbiza G Taylor JA Lopez J Furze S Wyld P Whyte EJ Stott G Wertz W Sullender M Trudel, J Gen Virol 1992 73 ( Pt 9) 2225 2234 1383404
19. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. JA Lopez R Bustos C Orvell M Berois J Arbiza B Garcia-Barreno JA Melero, J Virol 1998 72 6922 6928 9658147
20. Characterization of the epitope for anti human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. SJ Wu A Schmidt EJ Beil ND Day PJ Branigan C Liu LL Gutshall C Palomod J Furze G Taylor JA Melero P Tsui AM Del Vecchio M Kruszynski, J Gen Virol submitted
21. Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function. ND Day PJ Branigan C Liu LL Gutshall J Luo JA Melero RT Sarisky AM Del Vecchio, Virol J 2006 3 34 16723026 10.1186/1743-422X-3-34
22. Palivizumab in the prophylaxis of respiratory syncytial virus infection. S Cardenas A Auais G Piedimonte, Expert Rev Anti Infect Ther 2005 3 719 726 10.1586/14787210.3.5.719 16207163
23. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. S Johnson SD Griego DS Pfarr ML Doyle R Woods D Carlin GA Prince S Koenig JF Young SB Dillon, J Infect Dis 1999 180 35 40 10.1086/314846 10353858
24. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. JE Crowe CY Firestone R Crim JA Beeler KL Coelingh CF Barbas DR Burton RM Chanock BR Murphy, Virology 1998 252 373 375 10.1006/viro.1998.9462 9878616
25. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. RA Karron PF Wright JE Crowe Jr. ML Clements-Mann J Thompson M Makhene R Casey BR Murphy, J Infect Dis 1997 176 1428 1436 9395351
26. Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. MN Teng PL Collins, J Virol 1998 72 5707 5716 9621029
27. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. MN Teng SS Whitehead PL Collins, Virology 2001 289 283 296 10.1006/viro.2001.1138 11689051
28. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. S Techaarpornkul N Barretto ME Peeples, J Virol 2001 75 6825 6834 11435561 10.1128/JVI.75.15.6825-6834.2001
29. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. S Techaarpornkul PL Collins ME Peeples, Virology 2002 294 296 304 10.1006/viro.2001.1340 12009871
30. Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein. PJ Branigan C Liu ND Day LL Gutshall RT Sarisky AM Del Vecchio, Virol J 2005 2 54 16014172 10.1186/1743-422X-2-54